Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843230 · ClinicalTrials.gov registry record
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 30
- Enrollment target
NCT02843230: Completed study, sponsored by Massachusetts General Hospital.
NCT02843230 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02843230 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This research study aims to predict treatment response to anti-angiogenic therapy (Avastin) using advanced magnetic resonance imaging (MRI) and spectroscopy (MRS) for Glioblastoma patients.
Interventions
- DEVICE MRI
- RADIATION Avastin
- RADIATION Lomustine
- RADIATION Temozolomide
- DEVICE MRS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2022-01-31 |
What the finished NCT02843230 record still lists
NCT02843230 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which MRI is the first listed.
NCT02843230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02843230 about?
NCT02843230 is a clinical study titled "Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI". This research study aims to predict treatment response to anti-angiogenic therapy (Avastin) using advanced magnetic resonance imaging (MRI) and spectroscopy (MRS) for Glioblastoma patients.
What is the current status of trial NCT02843230?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2016-08-01. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT02843230?
The interventions under investigation include: MRI (DEVICE), Avastin (RADIATION), Lomustine (RADIATION), Temozolomide (RADIATION), MRS (DEVICE).
Who is sponsoring clinical trial NCT02843230?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI